Allianz Se Blueprint Medicines Corp Transaction History
Allianz Se
- $3.75 Trillion
- Q1 2025
Shares
2 transactions
Others Institutions Holding BPMC
# of Institutions
391Shares Held
68.5MCall Options Held
1.54MPut Options Held
1.08M-
Black Rock Inc. New York, NY6.65MShares$853 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.64MShares$852 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.42MShares$695 Million0.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.85MShares$494 Million5.51% of portfolio
-
Wellington Management Group LLP Boston, MA3.07MShares$394 Million0.05% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.66B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...